Learn More
Since 2005, the European Union has had a regulatory pathway through which biosimilars are approved centrally by the European Medicines Agency (EMA), as with pioneer biologics. So far, biosimilars have been approved in four separate classes: somatropins, erythropoiesis-stimulating agents (ESAs), granulocyte colony-stimulating factors (G-CSFs) and, most(More)
New-onset refractory status epilepticus (NORSE) is a rare but challenging condition occurring in a previously healthy patient, often with no identifiable cause. We describe the electro-clinical features and outcomes in a group of patients with NORSE who all demonstrated a typical magnetic resonance imaging (MRI) sign characterized by bilateral lesions of(More)
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical to a reference biological product and cost less. Because bringing biosimilars to the market currently requires large investments of money, fewer biosimilars are expected to enter the biologics market(More)
OBJECTIVE To compare comorbidities and use of surgery and palliative care between men and women with intracerebral hemorrhage (ICH). METHODS The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study is a prospective, multicenter, case-control study of ICH risk factors and outcomes. We compared comorbidities, treatments, and use of(More)
A neuro-controlled bionic arm will be able to allow an amputee to move his or her prosthetic arm as if it is a real limb simply by thinking. The arm also empowers patients with more natural movement, greater range of motion and restores lost function. To design a system which connects the brain to the arm through nerves is possible only when the system will(More)
This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into account the generic free riding problem. It demonstrates that changes in competition along dimensions other than retail price--such as(More)
s: Thematic Session – Industrial and Chemical Disasters THEMATIC SESSION C1: INDUSTRIAL AND CHEMICAL DISASTERS Chairperson: K.C Gupta Director General, National Safety Council of India , Navi Mumbai
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars—drugs that are very similar but not identical to a reference biological product and cost less. Because bringing biosimilars to the market currently requires large investments of money, fewer biosimilars are expected to enter the biologics market(More)
  • 1